Rick Simpson Oil (RSO) in Southeastern Connecticut: The Complete Guide by OilWell Cannabis

Understanding Rick Simpson Oil: From Nova Scotia to New London County

Who is Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada — a small maritime community not unlike our own coastal towns here in Southeastern Connecticut. He wasn’t a doctor, scientist, or medical professional. He was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. In a story that resonates with many here in the Thames River Valley who’ve faced workplace injuries in our shipyards, fishing fleets, or construction sites, Simpson found that the medications prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study — originally intended to demonstrate harm — became foundational in Simpson’s advocacy, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment came in 2003. Three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has ever been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil .

Important context: Simpson’s account is presented here as personal testimony. The absence of clinical documentation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement that eventually reached every corner of New England, including our Southeastern Connecticut communities from Mystic to Norwich.

The Crusade — Spreading the Oil Across Borders

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free — no charge, no profit margin, no dispensary licensing fees that Connecticut patients now face. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, and insomnia .

In 2005, Simpson’s story reached a global audience through the documentary Run From The Cure, which became foundational in cannabis communities. For many in Southeastern Connecticut’s veteran population and chronic illness support groups, this film was their first introduction to concentrated cannabis oil as medicine .

But Simpson’s advocacy brought him into direct conflict with Canadian law. The RCMP raided his property in 2005 and 2009, charging him with cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada for Europe, continuing his advocacy from Croatia and the Netherlands .

In 2012, he published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his advocacy platform .

Throughout his career, Simpson maintained that cannabis oil could cure cancer and many other diseases, and that pharmaceutical companies and government agencies were actively suppressing this knowledge. He framed his work as a fight against institutional corruption .

Important context: Simpson’s conspiratorial framing is noted here without endorsement. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance. Here in Southeastern Connecticut, where we’ve seen pharmaceutical influence in our own healthcare systems and where many Navy veterans have experienced institutional medical failures with PTSD and chronic pain treatment, these sentiments resonate deeply — even as we commit to a more evidence-based approach.

The Traditional RSO Protocol — Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core recommendation was consuming 60 grams of concentrated cannabis oil over approximately 90 days. Here’s the detailed breakdown as Simpson described it :

Goal: Consume 60 grams (approximately 60 mL) of high-THC cannabis oil over roughly 90 days.

Titration Schedule:

• Week 1: Dose the size of half a grain of rice (~10-15mg) three times daily. Total: 30-45mg/day.
• Weeks 2-5: Double the dose every four days to build tolerance. Target: 1 gram (1,000mg) per day by week five, divided into three doses of ~333mg each.
• Weeks 5-12: Maintain 1 gram/day until all 60 grams are consumed.

Administration Methods:

• Primary: Oral/sublingual — placing oil under the tongue or swallowing
• Secondary: Topical application for skin cancers, covered with bandages changed every 3-4 days
• Not recommended as primary: Inhalation (though acknowledged for immediate symptom relief)

Tolerance and Psychoactive Effects:

• Simpson claimed patients develop tolerance within 3-4 weeks
• Recommended nighttime dosing initially to sleep through early psychoactive effects
• Warned against driving or operating machinery during titration
• Advised informing family members about expected effects

Post-Protocol Maintenance: After completing 60 grams, Simpson recommended 1-2 grams per month indefinitely.

Dietary Recommendations: Reduce sugar, avoid processed foods, improve overall nutrition (though this was less systematic than his oil protocol).

Important Context for Evaluating This Protocol

This protocol was designed by one person based on personal experience, not clinical trials. Several critical points apply:

• No controlled trial validation: No published randomized controlled trials, cohort studies, or well-documented case series exist evaluating this specific 60-gram/90-day protocol for any cancer type or condition.
• Assumes crude, unstandardized material: The 60-gram quantity assumes single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely.
• Very high THC exposure: At peak dosing (1 gram/day of 60-90% THC oil), patients consumed approximately 600-900mg of delta-9 THC daily — far exceeding anything studied clinically. For context, FDA-approved dronabinol is typically dosed at 2.5-20mg/day.
• Real risks at these doses: Consuming 600-900mg of THC daily carries serious risks including severe intoxication, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• Oncology context: Active cancer patients are medically complex. Using unregulated, unstandardized cannabis oil as primary treatment — potentially in place of proven therapies — introduces harm beyond the oil itself.

What Traditional Rick Simpson Oil Was as a Product

Source Material: High-THC, indica-dominant cannabis strains with no standardization.

Extraction Solvent: Naphtha (petroleum-based) or 99% isopropyl alcohol — neither food-grade. Naphtha may contain benzene, toluene, and other carcinogens. This is a significant safety issue for anyone in Southeastern Connecticut considering DIY extraction.

Extraction Process: Bucket + solvent + agitation → filter → rice cooker evaporation → syringe storage. No temperature control, no solvent recovery system, no safety equipment.

Appearance: Nearly black, thick, tar-like oil with strong cannabis odor and possible solvent-residual smell.

Cannabinoid Profile: Fully decarboxylated, THC-dominant (60-90% estimated), with minor cannabinoids at natural, uncontrolled ratios. No lab verification.

Terpene Content: Minimal to none. High-heat evaporation destroyed terpenes.

Standardization: None. Every batch varied based on starting material, growing conditions, solvent purity, extraction technique, and maker’s process.

Residual Solvent Risk: This is one of the most significant safety concerns. Incomplete solvent purging leaves potentially harmful residues. Modern extraction uses food-grade ethanol or supercritical CO₂ specifically to address this.

Simpson’s Claims vs. The Evidence Record

Simpson claimed RSO could cure cancer and many other diseases. Let’s evaluate this against actual evidence using the same standards we apply throughout this document.

What Simpson Was Not: Not a scientist, physician, pharmacologist, or researcher. No formal medical training. Never designed, conducted, funded, or published a clinical trial. Never submitted results to peer review. His evidence base consisted entirely of personal experience and testimonials with no controls, verification, or blinding.

What Preclinical Literature Shows: In vitro studies demonstrate THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines . Animal models show some tumor-growth inhibition. These findings are scientifically interesting but have not translated into proven human cancer cures.

What Preclinical Literature Does NOT Show: No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer. Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been exploratory and have not produced results supporting cancer-cure claims .

Institutional Positions:

• U.S. National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for potential anticancer effects in lab and animal models but does not endorse cannabis or cannabis oil as cancer treatment .
• FDA: Has not approved any cannabis plant product for cancer treatment. Only FDA-approved cannabinoid products are for specific other indications: Epidiolex (CBD) for certain seizure disorders, dronabinol/nabilone for chemo nausea and AIDS-related wasting [1].
• Health Canada: Never approved RSO or cannabis oil as cancer cure.
• NCCIH: Strongest cannabinoid evidence is for rare epilepsies, chemo nausea/vomiting, and HIV/AIDS appetite — not cancer cure [1].

What Simpson Got Right: He drew attention to cannabinoids as a serious biomedical research area when the world was ignoring it. His advocacy helped create conditions for the legal cannabis industry and research infrastructure we have today. The term “RSO” remains the most recognized name for full-spectrum cannabis extract.

What He Overstated: The leap from preclinical signals to cancer cure was not supported by human evidence then, and it is not supported now. Encouraging patients to rely on RSO as primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative medicine.

The Legacy and Evolution of Modern RSO

The term “RSO” is now used broadly and loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to what Simpson originally made. In Connecticut dispensaries today, RSO can refer to almost any full-spectrum extract sold in syringe format, regardless of extraction method or cannabinoid profile.

Simpson himself has been critical of commercial products using the RSO name while departing from his original method and philosophy. He gave oil away for free and urged DIY production. The modern cannabis industry has commercialized, standardized, and regulated what he distributed freely. Whether that evolution represents improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, regulatory gatekeeping) depends on perspective.

What is not in dispute is that modern RSO has evolved substantially. The table below shows how OilWell’s formulated RSO compares to traditional RSO.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source Material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction Method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid Profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene Content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab Testing	Not available or performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
Residual Solvents	Significant risk with naphtha	Controlled and tested to FDA Class 3 limits
Dosing Precision	Approximate, syringe-based	Measured per mL with graduated dropper (0.1 mL increments)
Product Formats	Single thick oil only	Sublingual oil AND vape cartridge with format-specific formulas
THCa Preservation	No — fully decarboxylated by heat	Yes — THCa included as separate ingredient at 1,500 mg
Evidence Approach	Anecdotal, personal testimony	Research-backed, evidence-weighted with 29 peer-reviewed citations

Why OilWell’s Formulas Diverge from Traditional RSO

Multi-Cannabinoid Approach: Traditional RSO relied on whatever single strain the maker grew. OilWell’s formulas intentionally include seven cannabinoids because entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

Terpene Preservation: Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5% with a specific seven-terpene profile because terpene bioactivity is plausible and supported at the preclinical level [20][21][23][24][25][26][27][28][29].

THCa as Separate Ingredient: Traditional RSO fully decarboxylated everything. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

Reduced Delta-9 THC Dominance: Traditional RSO was 60-90% delta-9 THC. OilWell’s sublingual formula uses only 90 mg delta-9 THC while incorporating 6,000 mg delta-8 THC and distributing remaining cannabinoids across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg).

Product Format Innovation: Simpson envisioned only one format: oral oil from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulations acknowledging different pharmacokinetic profiles [14].

Solvent Safety and Extraction Evolution

Traditional RSO production used naphtha or isopropyl alcohol — neither food-grade. Naphtha is a petroleum hydrocarbon mixture that may contain benzene, toluene, and other toxic compounds. Incomplete solvent purging leaves potentially harmful residues.

Modern cannabis extraction uses food-grade ethanol or supercritical CO₂, allowing much more complete solvent removal. Finished products can be tested for residual solvents using validated analytical methods. This is one of the most straightforward improvements the modern regulated cannabis industry has made over traditional RSO production.

This evolution connects directly to product-quality discussion in GENERAL KNOWLEDGE: labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products [1][10][11][14].

The Decarboxylation Question

Traditional RSO was fully decarboxylated. The heat involved in rice cooker evaporation (60-80°C for naphtha, ~82°C for isopropyl alcohol) converted essentially all THCa into delta-9 THC. Acidic cannabinoids were lost as distinct compounds.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by THCa evidence showing potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism — benefits lost when THCa converts to THC [12].

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with low boiling points (21-157°C). Most cannabis terpenes volatilize below 180°C. Traditional RSO destroyed terpenes in two ways: dissolving them into solvent wash, then evaporating them during high-heat solvent removal.

Traditional RSO was essentially a cannabinoid-only product despite being derived from a terpene-rich plant.

OilWell’s formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. The entourage-effect literature provides theoretical framework for why preserving terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof remains limited [20][29].

Evidence Standards Then and Now

Rick Simpson operated pre-legalization, pre-lab-testing. When he began making oil in the early 2000s, cannabis was illegal in Canada and most of the world. No regulatory framework, no standardized testing, no legal pathway for clinical research, no peer-reviewed journals dedicated to cannabis therapeutics. Personal experience was the primary evidence currency.

Simpson’s methods reflected those constraints: anecdotal evidence, unstandardized production, untested claims. This is not necessarily a moral failing — it’s a description of his environment.

This document takes a fundamentally different approach. GENERAL KNOWLEDGE applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews, institutional summaries, then preclinical literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled.

The intent is to honor RSO’s historical origin while committing to modern cannabinoid science standards. Where Simpson relied on testimony, this document relies on published literature and institutional sources.

Simpson’s Protocol vs. Modern Dosing Considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison to modern, standardized, multi-cannabinoid formulation is not straightforward — the products are fundamentally different.

Key Differences:

• Cannabinoid Concentration: OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid Ratios: Simpson’s oil was 60-90% delta-9 THC. OilWell’s formula distributes 16,590 mg across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg).
• Terpene Presence: Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5%.
• Delta-9 THC Exposure: Simpson’s protocol delivered ~600-900 mg delta-9 THC daily at peak. OilWell’s sublingual formula contains only 90 mg delta-9 THC in the entire 30 mL bottle (3 mg/mL).

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by per-compound evidence in GENERAL KNOWLEDGE and responsible titration principles accounting for each cannabinoid’s safety profile.

About OilWell Cannabis and the OilWell RSO Formula: Our Commitment to Southeastern Connecticut

The Origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas — a city built on oil, medicine, and innovation, much like Southeastern Connecticut was built on maritime industry, submarine technology, and healthcare excellence. Colin grew up in McAllen, Texas, right across the river from Reynosa, Mexico — a region not unlike the economic contrasts we see between our coastal tourist economy and our struggling industrial towns. The McAllen-Reynosa area, known as the Borderplex, faces challenges similar to those in parts of New London County: poverty, limited opportunities, and the harsh realities of industries that don’t always protect their workers.

Colin’s childhood was marked by exposure to violence, loss of friends to prison or death, and the need to leave home at sixteen. These experiences shaped a philosophy that resonates with our own Southeastern Connecticut values: resilience, self-reliance, and a deep skepticism of institutions that promise safety but deliver harm.

Despite the dangers, Colin chose cannabis over harder paths. He grew up in the traditional pre-legalization cannabis world, learning the plant intimately while operating in the shadows. He later became a formally trained software engineer and did custom development work for Baylor College of Medicine — one of the nation’s most prestigious medical institutions, not unlike our own Yale-New Haven healthcare network that serves Southeastern Connecticut. That combination of deep cannabis knowledge and medical-grade technical precision defines OilWell’s approach and sets us apart from every hemp brand operating in Connecticut.

Bentley’s Story: The Foundation of Everything

OilWell’s origin story begins with a dog named Bentley — a rescue who became family. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering.

For Colin, giving up on Bentley was not an option. He’d already faced too much loss. In a desperate search for alternatives, a rescue worker named Jessica asked the question that changed everything: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but it was recreational. He’d never explored therapeutic applications. Determined to save Bentley, he learned to create CBD golden paste. It was not a cure, but it was hope. And that hope delivered what veterinary medicine said was impossible: Bentley got up, walked over, and brought his ball to play. From paralyzed facing euthanasia to fetching his ball. This was not placebo — dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized formulas for every age-related condition Bentley faced. Neurodegeneration led to understanding CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led to CBC’s role in neurogenesis. Glaucoma led to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led to multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone couldn’t address neurodegeneration, dementia, glaucoma, and arthritis simultaneously. Minor cannabinoids became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into cannabis beyond getting high. It became a mission to create real solutions that alleviate pain and suffering, not just for pets but for people. Bentley’s story is OilWell’s foundation, driving our commitment to quality, innovation, and compassionate care.

Colin’s Personal Journey: From Xanax to Peace

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction — conditions that affect far too many in Southeastern Connecticut’s veteran and maritime worker communities. When he decided to break free from Xanax, he did it cold turkey using cannabinoid knowledge developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form for insomnia and severe PTSD. This isn’t theoretical knowledge — he lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits Colin discovered through Bentley became the core of his work. He’s developed formulas that doctors use for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 Houston: Seven Features, Four Years, One Voice

Between September 2019 and April 2023, ABC13 Houston — the ABC affiliate serving America’s fourth-largest city — featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers.

No other Houston cannabis operator appears with that frequency or breadth. When ABC13 needed to explain a new cannabis product, it called Colin. When Texas DSHS reversed course on Delta-8 overnight, it called Colin. When President Biden announced marijuana pardons and the station needed someone who’d personally lived with a cannabis conviction to provide context, it called Colin.

September 15, 2019 — “Texas CBD businesses booming”
Colin’s foundational quote: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This quote from 2019 — years before these formulas were published — is the seed of everything OilWell became. The open-source formula publication, evidence-based research documentation, refusal to make unsupported claims: all trace back to this principle.

March 22, 2021 — “Entrepreneur creates direct-to-consumer business”
Colin as ecosystem builder helping other entrepreneurs: “Pain comes in a lot of different forms.” This speaks to every Southeastern Connecticut community dealing with any form of suffering — from maritime injuries to veteran trauma to chronic illness.

May 24, 2021 — “What is Delta 8 THC”
Steve Campion’s investigative feature included Colin’s iconic exchange: “Maybe you want to get high” — radical honesty on mainstream television that became one of his most referenced moments.

August 20, 2021 — “Houston CBD shop giving away free products for COVID vaccine”
OilWell gave away approximately $35,000 in product (1,000 caviar pre-rolls) to encourage COVID-19 vaccination, coordinating with the city of Houston. Community health action during a pandemic — this is the kind of commitment that resonates with Southeastern Connecticut’s strong sense of collective responsibility.

October 19, 2021 — “Texas ban over Delta 8”
When Texas DSHS classified Delta-8 as Schedule I overnight, Colin proactively removed all products before enforcement and warned other operators who were unknowingly shipping Schedule I narcotics. This ethical leadership during crisis defines OilWell’s character.

October 7, 2022 — “Biden marijuana pardon”
This feature revealed Colin’s personal marijuana conviction history: “You face challenges with housing, loans, and banking, I mean with about everything. I would love to see people not get hurt for this anymore.” This personal dimension transforms the entire media record — every quote carries additional weight when you understand the person saying it has lived the consequences of cannabis criminalization.

April 21, 2023 — “Marijuana industry getting creative”
Colin’s “Renaissance” framing: “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.” For Southeastern Connecticut, where we’re watching our own cannabis industry evolve post-legalization, this perspective is empowering.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, quotable, accessible voice in Houston’s legal cannabis industry. That kind of recognition cannot be purchased — it can only be earned. For Southeastern Connecticut residents evaluating which cannabis company to trust, this media record provides third-party verification that no marketing copy could replicate.

Our Philosophy: Four Core Principles

OilWell’s RSO is not traditional Rick Simpson Oil. It’s a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in deliberate, evidence-motivated ways designed to solve problems that limited Rick Simpson’s original vision.

1. Accessibility Over Gatekeeping
No medical card is required. Anyone age 21+ can purchase. We ship nationwide across the United States and internationally to customers who verify local legality. While Connecticut has legal adult-use cannabis, our dispensaries are still limited in number and location. For residents in Stonington, Old Lyme, or Montville who can’t easily reach a dispensary in New London or Norwich, our direct-to-consumer model provides access that state-licensed retailers cannot match. We ship directly to your door in Southeastern Connecticut with full documentation.

2. Patient-Controlled Potency
THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency. While Connecticut dispensaries sell pre-activated products, we give you the control through chemistry rather than rhetoric.

3. Open-Source Formulas
We publish our complete formulas publicly — every cannabinoid, every milligram, every percentage — so anyone who cannot afford our products can source ingredients and make their own version. Simpson gave his oil away for free; we adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product AND publishing the recipe.

4. Evidence-Informed, Not Evidence-Overstating
The GENERAL KNOWLEDGE section in this document represents our commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed literature; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance and the THCa Legal Framework: What Connecticut Residents Need to Know

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of our RSO product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in Connecticut.

THCa: The Legal Distinction That Changes Everything
THCa (tetrahydrocannabinolic acid) is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it hasn’t been converted to delta-9 THC.

You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams delta-9 THC, this produces approximately 1,405 milligrams total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

You can also transfer a controlled portion into a second oven-safe container, decarboxylating only what you intend to use while preserving the remainder in raw THCa form.

Conversion Chemistry: THCa molecular weight is 358.47 g/mol. The conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting loss of a CO₂ molecule.

Important Legal Notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with local laws. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

For Connecticut residents: while adult-use cannabis is legal in our state, you may still face workplace drug testing policies that don’t distinguish between legal hemp-derived products and illegal marijuana. THCa in its raw form will not cause positive THC tests, but decarboxylated (activated) THCa and delta-8 THC will trigger positive results. Be informed about your employer’s policies.

Open-Source Formulas: Why We Publish Everything

We publish our complete RSO formulas publicly — every cannabinoid, every milligram, every percentage — so anyone who cannot afford our products can source ingredients and make their own version.

If you’re facing financial hardship in Southeastern Connecticut — whether you’re a fishing family dealing with seasonal income, a veteran on fixed benefits, or anyone struggling with Connecticut’s high cost of living — you can access our formulas. That’s the point.

The formulas for our RSO Sublingual Oil and RSO Vape Cartridge are detailed later in this document. We also publish the original CBD golden paste recipe that saved Bentley’s life, so any pet owner facing a similar crisis can make it themselves.

CBD Golden Paste Recipe for Pets:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size; consult veterinarian)

Instructions: Mix turmeric and water in saucepan over low heat until thick paste forms (7-10 minutes). Add coconut oil and pepper. Cool and store in refrigerator up to two weeks. Mix CBD oil into paste before serving. Start with low dose and monitor.

This recipe — published for free years before our RSO formulas — demonstrates that our open-source ethos is consistent behavior, not marketing strategy.

The Decarboxylation Choice: Patient-Controlled Potency

Traditional RSO was always fully decarboxylated — you had no choice about psychoactivity. Our sublingual formula creates three distinct usage options:

Option 1: Raw, No Heat (500 mg total cannabinoids per 0.25 mL/one-quarter dropper)
All 1,500 mg stays as THCa — completely non-psychoactive. Provides anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. Compatible with work, driving, and daytime use with zero impairment. Perfect for Southeastern Connecticut residents who need to function at work, whether on the fishing boats, at Electric Boat, or in the casinos.

Option 2: Fully Activated, Home Decarboxylation
Heating at 260°F for 45-60 minutes converts 1,500 mg THCa into ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC yields ~1,405 mg total — achieving psychoactive potency comparable to traditional illegal RSO, 100% legally because decarboxylation occurs at your discretion after purchase. For Connecticut residents who want therapeutic strength for nighttime use, chronic pain, or cancer support.

Option 3: Vape, Auto-Decarboxylation
Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Fastest-onset RSO delivery method available — 1-2 minutes. Perfect for breakthrough pain, panic attacks, or acute nausea.

This design puts potency control entirely in your hands — aligning with Rick Simpson’s principle that patients should control their medicine, but implementing it through actual product chemistry.

Solvent-Free Production

Our RSO is not a traditional extraction product. It’s a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents in the finished product.

We use organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil is food-grade lipid carrier that facilitates sublingual absorption and provides neutral taste — a significant improvement over traditional RSO’s tar-like consistency and solvent-residual odor.

Third-party lab testing covers:

• Cannabinoid potency (HPLC/UHPLC analysis, ±2% accuracy)
• Terpene profile
• Pesticides (400+ compound screening via LC-MS/MS and GC-MS/MS)
• Heavy metals (ICP-MS testing for arsenic, cadmium, lead, mercury)
• Residual solvents (FDA Class 3 limits <5,000 ppm via headspace GC)
• Microbial contaminants (E. coli, Salmonella, Aspergillus)

Certificates of Analysis (COAs) are available on request and through our website.

The Broader OilWell Product Portfolio

Beyond RSO, we produce a range of cannabinoid products developed from Colin’s formulation knowledge:

Asshole Peach — Our most popular product. Peach-flavored gummy rings with 268 mg total cannabinoids per piece (28 mg delta-9 THC, 50 mg delta-8 THC, 20 mg delta-10 THC, 20 mg THCo, 100 mg CBD, 50 mg CBG). Particularly favored by veterans for PTSD and pain relief. For Southeastern Connecticut’s significant veteran population — many stationed at Naval Submarine Base New London or who’ve settled in Groton, Waterford, and Ledyard after service — this product offers a familiar format with serious therapeutic potential.

Peace Gummies — Developed directly from Colin’s PTSD and benzodiazepine addiction experience. Helped him quit Xanax cold turkey. Available in peach form with 320 mg total cannabinoids per piece (30 mg CBN, 15 mg delta-9 THC, 25 mg delta-8 THC, 100 mg CBD, 150 mg CBG). Also available in vape form for quick relief. For Connecticut residents dealing with the anxiety and insomnia that plague our high-stress modern lives.

SWEETEMintz — Sugar-free vegan peppermint hard candy with 28 mg delta-9 Nano THC, 100 mg Nano CBD, 50 mg CBG isolate. Zero sugar, 100% vegan — designed for diabetic and health-conscious consumers. Perfect for Southeastern Connecticut’s aging population managing diabetes while seeking cannabinoid relief.

Custom Creations — We design tailored products on request for specific cannabinoid ratios, delivery formats, or health circumstances, including formulations for vegans, diabetics, and those with specific dietary needs. Whether you’re dealing with the unique challenges of Lyme disease from our tick-heavy region or need a formulation compatible with maritime work schedules, we can create it.

Two Product Formats: Sublingual Oil and Vape Cartridge

We offer our RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg/mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility (works with standard vape batteries available at any Connecticut smoke shop)
• Onset: 1-2 minutes (fastest cannabinoid delivery)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable based on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

Complete RSO Guide — Our full product guide with science, competitive analysis, protocols, and ordering information.

When to Use Each Format in Southeastern Connecticut

Use Case	Recommended Format	Rationale	Southeastern Connecticut Example
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset	Breakthrough pain while working on a fishing boat off Fishers Island
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration	All-night pain relief for arthritis flare-up in Ledyard
Maximum bioavailability	Sublingual	13-19% absorption	Getting most medicine from each dose on a fixed income in Norwich
Portability/discretion	Vape	Compact, no measuring	Managing symptoms discreetly at Mohegan Sun or Foxwoods
Precise dosing control	Sublingual	Graduated dropper	Titrating carefully for elderly parent in Stonington
Daytime non-psychoactive use	Sublingual (raw)	Zero impairment	Working at Electric Boat in Groton or teaching at Connecticut College
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Full therapeutic strength	Severe PTSD symptoms or cancer-related pain in New London

Competitive Comparison: OilWell RSO vs. Connecticut Alternatives

OilWell RSO vs. Connecticut Medical Marijuana Dispensary RSO

Dimension	CT Dispensary RSO	OilWell RSO
Cannabinoid Profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG Content	0 mg	3,000 mg
CBN Content	0 mg	750 mg
CBC Content	0 mg	750 mg
Patient-Controlled Potency	No — always fully psychoactive	Yes — THCa raw until you heat it
Access Requirements	CT medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying Conditions	Cancer, PTSD, chronic pain, etc.	None required
Delivery	Must travel to dispensary (New London, Montville, or beyond)	Ships directly to your Southeastern Connecticut address
Farm Bill Compliant	No — state medical cannabis program	Yes — <0.3% delta-9 THC

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total Cannabinoids	1,000 mg	16,590 mg
CBD Content	~950 mg	4,500 mg
CBG Content	15.5 mg	3,000 mg
CBN Content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible)	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive Option	No meaningful psychoactive effect	Yes — via THCa decarboxylation and delta-8 THC
Approximate Price	$40-50	$129.99

Bottom Line for Southeastern Connecticut: While Connecticut’s adult-use dispensaries offer convenience for those near New London or Montville, they provide only THC-dominant RSO that lacks the multi-cannabinoid synergy our formula offers. Hemp CBD RSO products lack psychoactive options and contain far lower total cannabinoids. OilWell delivers a clinically superior, patient-controlled, legally compliant alternative that ships directly to your door anywhere from Mystic to Norwich.

Condition-Specific Usage Context for Southeastern Connecticut

Important Disclaimer: These usage contexts are informed by cannabinoid research cited in GENERAL KNOWLEDGE and our formulation rationale. They are NOT medical prescriptions, NOT FDA-approved treatment protocols, and NOT substitutes for professional medical care. These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, take medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Always consult your physician. For Southeastern Connecticut residents, this means talking to doctors at Lawrence + Memorial Hospital, Backus Hospital, or your primary care provider in Groton, Waterford, or Stonington. Be honest about cannabinoid use so they can monitor for interactions.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence: delta-8 THC antiemetic [9], delta-9 THC nausea evidence [1][13], CBD anxiolytic buffering [3]

Chronic Pain (Fibromyalgia, Arthritis, Maritime Injuries)

• Daytime: 0.3-0.5 mL raw sublingual — anti-inflammatory without psychoactive impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep Support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, delivers 50 mg CBN — the dosage investigated in 2024 sleep literature
• At 1.0 mL, delivers 25 mg CBN — above threshold associated with reduced sleep disturbance
• Evidence: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety without impairment
• Nighttime: 1.0 mL sublingual — full profile including CBN for sleep architecture
• Evidence: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage evidence [20]

PTSD (Especially for Southeastern Connecticut Veterans)

• Daytime: 0.3-0.5 mL raw sublingual to manage hyperarousal without impairment
• Nightmare disruption: 1.0-2.0 mL decarboxylated sublingual 1 hour before sleep
• Acute flashbacks: 2-3 vape puffs for immediate relief
• Evidence: CBD PTSD research, delta-8 THC anxiolytic properties [9], CBN sleep support [16][17]

Lyme Disease Support
Southeastern Connecticut has among the nation’s highest Lyme disease rates. While not a primary treatment, our anti-inflammatory multi-cannabinoid approach may help manage:

• Daytime inflammation: 0.3-0.5 mL raw sublingual
• Nighttime pain: 0.5-1.0 mL decarboxylated sublingual
• Evidence: THCa COX-2 inhibition [12], CBD anti-inflammatory properties [4]

General Titration Principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications (especially important for Southeastern Connecticut’s many seniors on polypharmacy), and other factors.

Delivery and Global Accessibility: How Southeastern Connecticut Gets OilWell RSO

Shipping to Southeastern Connecticut
We ship nationwide via USPS Priority Mail (2-3 business days), FedEx, and UPS Ground (3-5 business days). For Connecticut addresses from Mystic to Norwich, Old Lyme to Stonington:

• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments (important for our humid coastal climate)
• Signature-required option available
• COAs and full documentation included for your records

Connecticut-Specific Legal Context
Adult-use cannabis is legal in Connecticut for those 21+, but there are still important considerations:

• Public consumption is illegal. Use at home.
• Driving under influence is illegal. Never drive after consuming psychoactive cannabinoids.
• Workplace policies may still prohibit cannabis use. Know your employer’s drug testing policy.
• Federal employees and those with security clearances must follow federal law, not state law.
• Federal transport across state lines: Our Farm Bill-compliant products are legal to ship, but carrying them across state borders personally enters a legal gray area.

International Shipping
We ship internationally with full documentation, COAs, and customs receipts. While Connecticut residents are unlikely to need international shipping, this capability matters for relatives overseas or for demonstrating the global reach of our legal framework. International customers accept all customs and legal responsibility.

Delivery Timeframes to Southeastern Connecticut Planning Region:

• Standard Shipping: 3-5 business days
• Expedited Shipping: 2-3 business days
• Express Shipping: 1-2 business days available

We ship from Houston, Texas, but our proprietary PANDEM1C SEO technology — with 14 million distinct geopolitical locations in its database and over 300 AI models — ensures our products are discoverable to patients searching for RSO in Groton, New London, Norwich, and every corner of Southeastern Connecticut.

How Our Formulas Connect to the Evidence

Every cannabinoid in our formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — has its own evidence profile in the GENERAL KNOWLEDGE section of this document. Every terpene — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — is covered with preclinical and review-level evidence.

When our RSO guide page makes specific claims about individual cannabinoids or terpenes, this document provides the source evaluation context — the same peer-reviewed citations, evidence-tier assessments, and cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to our own products. We do not exempt ourselves from the same evidence standards applied to the broader field.

As Colin said in 2019: people deserve the best possible version of information so they can give it a fair shot and decide for themselves whether it’s right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand — it’s a promise to our customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that has defined us from the day Bentley got up, walked across the room, and brought his ball to play.

GENERAL KNOWLEDGE: The Science Behind Every Molecule

Research Method and Evidence Weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic or preclinical literature when human data are sparse. This weighting matters because the evidence base is not evenly distributed.

CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

Institutional Baseline from NIH and Related Sources

• NCCIH states the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea/vomiting, and appetite/weight-loss indications in HIV/AIDS. It notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
• FDA has not approved the cannabis plant itself for medical use, although purified CBD (Epidiolex) and synthetic THC-like drugs (dronabinol, nabilone) have specific approvals [1].
• Safety concerns repeatedly highlighted include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination, labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH specifically warns over-the-counter CBD products may differ from labels and CBD has been associated with decreased alertness, gastrointestinal effects, liver-function abnormalities, and drug interactions [1].

Cannabinoid Evidence Profiles

CBD

• Strongest human evidence in seizure disorders [1][2]
• Anxiety: 2024 systematic review of 316 participants showed statistically significant anxiolytic signal but limited clinical sample [3]
• Pain: 2024 review concluded promising but heterogeneous, with trial quality limiting confidence [4]
• Sleep: 2023 insomnia review found methodologically weak literature with few objective assessments [5]
• Safety: 2023 review found real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]
• Bottom line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence concentrated in specific indications rather than broad wellness claims [1]-[6]

CBG

• Mostly review-level and preclinical; human evidence sparse [7][8]
• Pharmacology: Biosynthetic precursor with distinct pharmacodynamics spanning cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A signaling [7]
• Potential areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity — primarily pharmacology-led hypotheses [7][8]
• Caution: Commercially sold while evidence base remains thin; claims frequently outrun science [7]
• Bottom line: Promising minor cannabinoid with limited clinical validation [7][8]

Delta-8 THC

• Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11]
• Comparative pharmacology: 2022 review concluded delta-8 and delta-9 have broadly similar pharmacokinetic/pharmacodynamic behavior; delta-8 is partial CB1 agonist, less potent than delta-9 [9]
• Public-health literature: 2023 scoping review found evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong human trials; noted adverse consequences and regulatory/product-quality concerns [10]
• Manufacturing context: Commercial interest tied to greater stability and easier synthesis relative to naturally scarce plant levels; product-byproduct and lab-testing questions matter [11]
• Bottom line: Psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than consumers realize [9]-[11]

THCa

• Important chemically/formulation-wise, low on direct human therapeutic evidence [12]
• What it is: Acidic precursor of THC; may represent large share of THC-related content in raw plant material. Decarboxylates into THC during heating and can change over time during storage/processing [12]
• Psychoactivity: Does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays acidic and is not substantially decarboxylated [12]
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities, but not equivalent to established human outcomes [12]
• Bottom line: Best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage [12]

Delta-9 THC

• Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15]
• Institutionally best supported: NCCIH identifies relevance to chemo nausea/vomiting, appetite/weight loss in HIV/AIDS, some MS and pain outcomes, while stressing many other uses remain uncertain [1]
• Pain evidence: 2022 systematic review found high-THC products or comparable THC:CBD ratios may provide short-term pain benefit but increased dizziness, sedation, nausea, treatment discontinuation [13]
• Pharmacokinetics: Inhaled THC: effects within seconds-minutes, peak ~15-30 minutes, taper over few hours. Oral THC: later onset, later peak, longer duration [14]
• Mental-health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, plus concerning anxiety/depression signals in nontherapeutic settings [15]
• Broader safety: Anxiety/panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung-injury concerns [1][14][15]
• Bottom line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15]

CBN

• Weak human evidence; marketing moved ahead of data [12][16][17]
• Marketed for: Sleep and sedation, but clinical support far thinner than market suggests [16][17]
• Best direct review: 2021 narrative review screened 99 human-study abstracts, reviewed 8 full-text articles, found no clinical trials using validated sleep questionnaires or polysomnography that could substantiate strong sleep-promoting claims [16]
• Broader sleep literature: 2024 updated review concluded cannabis sleep research still doesn’t match scale of real-world use; need for better-designed, adequately powered trials remains substantial [17]
• Chemical context: THC can degrade toward CBN under certain conditions, explaining why CBN is often discussed in aging/oxidized cannabis contexts [12]
• Bottom line: Clearest example where cultural reputation is stronger than current clinical evidence base [16][17]

CBC

• Emerging, intriguing, overwhelmingly preclinical or review-based [18][19]
• Pharmacology: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, receptor behavior relative to better-known cannabinoids; highlights antinociceptive, antibacterial, anti-seizure areas as especially interesting research targets [18]
• Older literature: Review of animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological or antiproliferative relevance, but not yet strong evidence for patient-facing claims [19]
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products already sold despite little evidence establishing clinical efficacy or safety [18]
• Bottom line: Scientifically credible minor cannabinoid that deserves more research, not already-validated clinical active [18][19]

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review emphasizes terpene bioactivity is plausible but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Mostly review/preclinical, useful safety literature [20]-[22]
• Potential activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities, but overwhelming share from nonhuman/non-cannabis literature [21]
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22]
• Bottom line: Biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22]

Myrcene

• Mostly preclinical, very limited human evidence [20][23]
• Research summary: 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties and possible mechanisms, but explicitly states human studies lacking [23]
• Interpretation caution: Often invoked as proven sedating terpene explaining couch-lock or sleep effects — stronger claim than human evidence currently supports [20][23]
• Bottom line: Plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23]

Caryophyllene

• Among most mechanistically interesting because of direct cannabinoid-system relevance, but still mostly preclinical [24]
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, unusual and especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24]
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions repeatedly discussed, but human clinical confirmation limited [24]
• Bottom line: Arguably strongest candidate for terpene with cannabinoid-system significance, but should not be described as clinically proven for outcomes commonly attributed to it [24]

Pinene

• Promising preclinical literature, weak human clinical confirmation [20][25]
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized well-designed clinical trials lacking [25]
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25]
• Bottom line: Deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25]

Linalool

• Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]
• Research summary: Repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological/psychiatric contexts, while still emphasizing lack of robust human trials [25]
• Additional literature: Separate review discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story [26]
• Safety note: As with limonene, oxidized linalool hydroperoxides recognized allergens in dermatitis literature [22]
• Bottom line: Scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26]

Humulene

• Translationally interesting, but still early [20][27]
• Scoping-review findings: 2024 review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27]
• Interpretation caution: Findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27]
• Bottom line: One of more interesting terpene research targets, but remains far from clinically settled [27]

Terpinolene

• One of least clinically characterized terpenes in this file [20][28]
• Systematic-review findings: 2021 review screened 2,449 records, included 57 studies, concluded terpinolene has range of reported biological effects but evidence base still dominated by in silico, in vitro, and animal studies rather than human trials [28]
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not established compound-specific clinical effects [20]
• Bottom line: Biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28]

Research Limits and Interpretation

• Evidence base is highly uneven. CBD and delta-9 THC support most detailed human-facing statements; rest require more caution [1]-[29]
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. Common error is letting evidence from one category stand in for another
• Minor cannabinoids and terpenes are commercially interesting precisely because underexplored, but that also means claims often become inflated
• Product quality matters as much as molecule identity: labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14]
• For THCa particularly, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12]

Common Overstatements to Avoid

Overstatement: CBN is clinically proven sleep cannabinoid.
More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].

Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].

Overstatement: Terpenes in general have proven entourage effects in patients.
More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].

Overstatement: THCa is always nonpsychoactive.
More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].

Overstatement: Delta-8 THC is safe because it’s hemp-derived.
More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical Takeaways for Our Formulas

• Most evidence-developed actives: CBD and delta-9 THC
• Delta-8 THC is not trivial or purely mild; it’s psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9 THC
• THCa meaningfully changes with processing; should not be interpreted same way in raw, gently handled, and heated formats
• CBG/CBN/CBC scientifically credible but clinically immature compared with CBD and THC
• Listed terpenes likely highly relevant to aroma, flavor, potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

RSO Sublingual Oil: The Complete Formula

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

Additional Specifications:

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Carrier: Organic MCT oil
• Dosing: Graduated dropper with 0.1 mL increments
• Farm Bill Compliant: Yes — <0.3% delta-9 THC
• Convertible Potency: 1,500 mg THCa converts to ~1,315 mg delta-9 THC when heated

How to Use in Southeastern Connecticut:

• Daytime raw use: 0.3 mL (166 mg cannabinoids) for non-psychoactive anti-inflammatory support
• Evening decarbed use: 0.5 mL (277 mg cannabinoids) for full therapeutic effects
• Maximum strength: 1.0 mL (553 mg cannabinoids) decarboxylated for serious conditions
• Sleep support: 1.0-2.0 mL delivers 25-50 mg CBN for sleep architecture

RSO Vape Cartridge: The Complete Formula

Cannabinoid	Percentage	Approximate mg per gram
CBD	30%	300 mg
CBG	20%	200 mg
Delta-8 THC	15%	150 mg
THCa	10%	100 mg
CBN	10%	100 mg
CBC	10%	100 mg
Live Terpenes	5%+	50+ mg
Total	100%	900+ mg

Specifications:

• Format: 1-gram 510-thread cartridge
• Battery: Universal 510-thread compatibility
• Activation: Auto-decarboxylation at 400-450°F
• Onset: 1-2 minutes
• Farm Bill Compliant: Yes — <0.3% delta-9 THC at point of sale
• Convertible: 100 mg THCa → ~88 mg delta-9 THC when vaporized

How to Use in Southeastern Connecticut:

• Acute relief: 2-3 puffs for breakthrough pain, panic, or nausea
• Maintenance: 1-2 puffs every 2-3 hours as needed
• Sleep: 3-4 puffs 15 minutes before bed

Terpene Profile: Both Products

Seven Live Terpenes at 5% Concentration:

1. Limonene — Citrus-bright aroma, potential mood elevation, antioxidant and anti-inflammatory properties [20]-[22]
2. Myrcene — Earthy, musky notes, potential muscle relaxation and sedative effects (though human evidence limited) [20][23]
3. Caryophyllene (β-caryophyllene) — Pepper/spice aroma, selective CB2 receptor agonist, anti-inflammatory and neuroprotective potential [24]
4. Pinene — Forest-fresh pine scent, potential memory enhancement and bronchodilation (preclinical stage) [20][25]
5. Linalool — Floral lavender notes, potential anxiolytic and sedative effects, recognized allergen when oxidized [20][22][25][26]
6. Humulene — Earthy, woody aroma, potential anti-inflammatory and appetite-suppressing effects [20][27]
7. Terpinolene — Piney, fruity, sparkling notes, least clinically characterized but biologically interesting [20][28]

Sensory Experience: The terpene profile creates a complex aroma that evolves from bright citrus top notes through earthy mid-tones to floral and pine undertones. For Southeastern Connecticut residents familiar with our coastal pine forests and maritime air, these terpenes provide a sensory connection to our natural environment.

Therapeutic Rationale: Each terpene was selected based on preclinical evidence for potential synergy with our cannabinoid blend. Caryophyllene’s CB2 agonism may enhance anti-inflammatory effects of CBD and CBG. Limonene’s mood-elevating potential may complement THC’s psychoactivity. Linalool’s anxiolytic properties may buffer any anxiety from high cannabinoid doses. Pinene’s potential bronchodilation may benefit those with respiratory concerns.

How to Order OilWell RSO in Southeastern Connecticut

Step 1: Choose Your Product

• RSO Sublingual Oil ($129.99): For sustained relief, precise dosing, non-psychoactive daytime option
• RSO Vape Cartridge ($49.99): For fast relief, portability, acute symptom management
• Bundle both: For comprehensive coverage of all use cases

Step 2: Verify Your Age and Location

• Must be 21+ years old
• We ship to all addresses in Southeastern Connecticut Planning Region including:
  • New London, Groton, Norwich, Stonington, Mystic, Old Lyme, East Lyme, Waterford, Ledyard, Montville, and all surrounding towns
• No medical card required for Farm Bill-compliant products

Step 3: Place Your Order

• Website: OilWellCBD.com
• Phone: (832) 416-2816
• Email: [email protected]
• Instagram: @oilwellcbd

Step 4: Receive Your Shipment

• Standard shipping: 3-5 business days to Connecticut
• Discreet packaging with no cannabis branding
• Track your order via email confirmation
• Review your COA (Certificate of Analysis) upon receipt

Step 5: Begin Your Protocol

• Start low: 0.25-0.5 mL sublingual or 1-2 vape puffs
• Go slow: Assess effects over 2-3 hours before increasing
• Keep a journal: Track dose, timing, effects, and any side effects
• Stay connected: Email us with questions at [email protected]

Legal and Safety Information for Connecticut Customers

Age Requirement: 21+ only. We verify age for all orders.

THC Content Compliance: All products contain less than 0.3% delta-9 THC at point of sale, making them Farm Bill compliant and legal to ship to Connecticut.

FDA Disclaimer: These products have not been evaluated by the Food and Drug Administration. They are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.

Safety Warnings:

• May cause drowsiness or impairment
• Do not operate vehicles, boats, or machinery after consuming psychoactive cannabinoids
• Consult your physician before use, especially if pregnant, nursing, or taking medications
• Keep out of reach of children and pets
• Store in cool, dry place away from direct sunlight
• THCa will convert to THC over time with heat exposure; product potency may change if stored improperly

Legal Responsibility: Buyer is responsible for checking local laws. We ship with full documentation, but customer assumes all legal responsibility for possession and use. Void where prohibited by law.

Connecticut-Specific Notes:

• Adult-use cannabis is legal for 21+ in Connecticut, but public consumption remains illegal
• Workplace drug testing policies may still prohibit THC metabolites regardless of source
• Driving under influence of cannabis remains illegal under Connecticut law
• Possession limits: 1.5 ounces flower or equivalent in concentrates (our 30 mL bottle = approximately 1.5 grams equivalent under state law, well within limits)

Final Words: Why Southeastern Connecticut Chooses OilWell

From the Thames River to the Connecticut shoreline, from the submarine base to the casinos, Southeastern Connecticut residents deserve honest, effective, accessible cannabinoid medicine. We’ve built our company on the same values that define your communities: resilience in the face of hardship, skepticism of empty promises, appreciation for both tradition and innovation, and commitment to helping neighbors.

Our products are not mass-produced commodities. They are carefully crafted with the same intent Colin brought to Bentley’s formula — because someone’s life depends on getting this right. Every cannabinoid amount is precise. Every terpene is selected for purpose. Every batch is tested. And every formula is published because we believe transparency builds trust.

When you choose OilWell RSO, you’re not just buying a product. You’re joining a community of people who’ve said “enough” to pharmaceutical failures, “enough” to one-size-fits-all medicine, “enough” to black-market uncertainty. You’re choosing a company that has been vetted by major media, that has weathered regulatory storms with integrity, and that puts people before profits.

Whether you’re in New London dealing with chronic pain from years of maritime work, in Groton managing PTSD from military service, in Norwich seeking alternatives to opioids, or in Stonington looking for better sleep — we see you. We understand your needs because we’ve lived them. And we’re here to provide the most comprehensive, evidence-informed, patient-controlled RSO available anywhere in the United States, delivered directly to your door in Southeastern Connecticut.

This is more than cannabis oil. This is the culmination of a decade of formulation driven by love, loss, science, and survival. This is OilWell RSO. And this is for you, Southeastern Connecticut.

Order Now
Contact Us
[Call: (832) 416-2816]
[Instagram: @oilwellcbd]

OilWell Cannabis, 810 Richmond Avenue, Houston, TX 77006
Serving Southeastern Connecticut Planning Region and beyond with integrity, innovation, and care.

Age 21+ Only | Farm Bill Compliant | Third-Party Lab Tested | Open-Source Formulas | Made in Houston, Delivered to Connecticut